Agitation in Nursing Home Residents With Dementia (VIDEANT Trial): Effects of a Cluster-Randomized, Controlled, Guideline Implementation Trial

Journal of the American Medical Directors Association

Volumn 14, Issue 9, 2013, Pages 690-695

  Rapp, Michael A ^a,b   Mell, Thomas ^a   Majic, Tomislav ^a   Treusch, Yvonne ^a   Nordheim, Johanna ^a   Niemann Mirmehdi, Mechthild ^a   Gutzmann, Hans ^c   Heinz, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

Agitation; Dementia; Guideline; Nursing home; Trial

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT;

AGED; AGGRESSION; AGITATION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEMENTIA; DISRUPTIVE BEHAVIOR; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME; NURSING HOME PATIENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

AGITATION; DEMENTIA; GUIDELINE; NURSING HOME; TRIAL;

AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; CHOLINESTERASE INHIBITORS; CLUSTER ANALYSIS; DEMENTIA; FEMALE; GERIATRIC ASSESSMENT; GERMANY; HUMANS; INTERVENTION STUDIES; MALE; NURSING HOMES; PRACTICE GUIDELINES AS TOPIC; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME;

EID: 84884132138     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2013.05.017     Document Type: Article

References (33)

1. Bakker T.J., Duivenvoorden H.J., van der Lee J., et al. Integrative psychotherapeutic nursing home program to reduce multiple psychiatric symptoms of cognitively impaired patients and caregiver burden:randomized controlled trial. Am J Geriatr Psychiatry 2011, 19:507-520.
2. Chenoweth L., King M.T., Jeon Y.H., et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia:a cluster-randomised trial. Lancet Neurol 2009, 8:317-325.
3. Fossey J., Ballard C., Juszczak E., et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia:cluster randomised trial. BMJ 2006, 332:756-761.
4. Leone A.F., Standoli F., Hirth V. Implementing a pain management program in a long-term care facility using a quality improvement approach. JAm Med Dir Assoc 2009, 10:67-73.
5. Testad I., Aasland A.M., Aarsland D. Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. Int J Geriatr Psychiatry 2007, 22:916-921.
6. Lyketsos C.G., Lopez O., Jones B., et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment:results from the cardiovascular health study. JAMA 2002, 288:1475-1483.
7. Brodaty H., Draper B., Saab D., et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents:prevalence and predictors. Int J Geriatr Psychiatry 2001, 16:504-512.
8. Margallo-Lana M., Swann A., O'Brien J., et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001, 16:39-44.
9. Gruber-Baldini A.L., Boustani M., Sloane P.D., Zimmerman S. Behavioral symptoms in residential care/assisted living facilities:prevalence, risk factors, and medication management. JAm Geriatr Soc 2004, 52:1610-1617.
10. Devanand D.P. Behavioral complications and their treatment in Alzheimer's disease. Geriatrics 1997, 52:S37-S39.
11. Souder E., O'Sullivan P. Disruptive behaviors of older adults in an institutional setting. Staff time required to manage disruptions. JGerontol Nurs 2002, 29:31-36.
12. Sutor B., Rummans T.A., Smith G.E. Assessment and management of behavioral disturbances in nursing home patients with dementia. Mayo Clin Proc 2001, 76:540-550.
13. Beeri M.S., Werner P., Davidson M., Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002, 17:403-408.
14. Majic T., Pluta J.P., Mell T., et al. The pharmacotherapy of neuropsychiatric symptoms of dementia: A cross-sectional study in 18 homes for the elderly in Berlin. Dtsch Arztebl Int 2010, 107:320-327.
15. Alessi C.A., Yoon E.J., Schnelle J.F., et al. Arandomized trial of a combined physical activity and environmental intervention in nursing home residents: Do sleep and agitation improve?. JAm Geriatr Soc 1999, 47:784-791.
16. Tondi L., Ribani L., Bottazzi M., et al. Validation therapy (VT) in nursing home: A case-control study. Arch Gerontol Geriatr 2007, 44:407-411.
17. Neal M., Briggs M. Validation therapy for dementia. Cochrane Database Syst Rev 2000, 2:CD001394.
18. Cohen-Mansfield J., Werner P., Culpepper W.J., Barkley D. Evaluation of an inservice training program on dementia and wandering. JGerontol Nurs 1997, 23:40-47.
19. Seitz D.P., Brisbin S., Herrmann N., et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care:a systematic review. JAm Med Dir Assoc 2012, 13:503-506.
20. Cohen-Mansfield J., Thein K., Marx M.S., Dakheel-Ali M. What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home?. JAm Med Dir Assoc 2012, 13:400-405.
21. Consensus statement on improving the quality of mental health care in U.S. nursing homes: Management of depression and behavioral symptoms associated with dementia. JAm Geriatr Soc 2003, 51:1287-1298. American Geriatrics Society & American Association of Geriatric Psychiatry.
22. Rapp M.A., Decker A., Klein U., et al. Verhaltenssymptome bei Demenz in Pflegeeinrichtungen:Evaluation eines Tandemprojekts pflegerischer und ärztlicher Leitlinien (VIDEANT). [Behavioral symptoms in dementia in nursing homes: Evaluation design of a guideline implementation program.]. Zeitschrift für Gerontopsychologie & -psychiatrie 2010, 21:205-214.
23. Ballard C., Hanney M.L., Theodoulou M., et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009, 8:151-157.
24. National Institute for Health and Clinical Excellence guidelines for the treatment of dementia (NICE). Available at: Accessed June 19, 2013. http://publications.nice.org.uk/dementia-cg42.
25. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
26. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988, 24:653-659.
27. Cohen-Mansfield J. Measurement of inappropriate behavior associated with dementia. JGerontol Nurs 1999, 25:42-51.
28. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2013. Oslo:2012.
29. Donner A. Some aspects of the design and analysis of cluster randomization trials. J R Stat Soc Ser C Appl Stat 2002, 47:95-113.
30. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale. 2nd ed.
31. Banerjee S., Hellier J., Dewey M., et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011, 378:403-411.
32. Bergh S., Selbæk G., Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): Double blind, randomised, parallel group, placebo controlled trial. BMJ 2012, 344:e1566.
33. Bakken M.S., Engeland A., Engesæter L.B., et al. Increased risk of hip fracture among older people using antidepressant drugs: Data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013, 42:514-520.